CN111032086B - Cd38抗体 - Google Patents

Cd38抗体 Download PDF

Info

Publication number
CN111032086B
CN111032086B CN201880051751.2A CN201880051751A CN111032086B CN 111032086 B CN111032086 B CN 111032086B CN 201880051751 A CN201880051751 A CN 201880051751A CN 111032086 B CN111032086 B CN 111032086B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
cells
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880051751.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032086A (zh
Inventor
安妮·古比耶
约瑟芬·萨利姆
贝特里兹·古耶内切亚·科尔佐
帕斯卡·梅希尔
凯文·莫尔德
妮娜·艾斯勒
西蒙尼·菲利斯托
赫曼塔·巴鲁
比安卡·普林兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Belt Medical Co ltd
Original Assignee
Black Belt Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Medical Co ltd filed Critical Black Belt Medical Co ltd
Publication of CN111032086A publication Critical patent/CN111032086A/zh
Application granted granted Critical
Publication of CN111032086B publication Critical patent/CN111032086B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880051751.2A 2017-08-16 2018-08-16 Cd38抗体 Active CN111032086B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546336P 2017-08-16 2017-08-16
US62/546,336 2017-08-16
US201762582609P 2017-11-07 2017-11-07
US62/582,609 2017-11-07
PCT/EP2018/072272 WO2019034753A1 (en) 2017-08-16 2018-08-16 ANTIBODY CD38

Publications (2)

Publication Number Publication Date
CN111032086A CN111032086A (zh) 2020-04-17
CN111032086B true CN111032086B (zh) 2023-09-26

Family

ID=63259520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880051751.2A Active CN111032086B (zh) 2017-08-16 2018-08-16 Cd38抗体

Country Status (9)

Country Link
US (2) US11236173B2 (enExample)
EP (1) EP3668543A1 (enExample)
JP (1) JP7299873B2 (enExample)
KR (1) KR102770110B1 (enExample)
CN (1) CN111032086B (enExample)
AU (1) AU2018316522B2 (enExample)
CA (1) CA3072296A1 (enExample)
SG (1) SG11202000484TA (enExample)
WO (1) WO2019034753A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
US12453738B2 (en) 2019-03-12 2025-10-28 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
CA3142632A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
AU2021338773A1 (en) 2020-09-10 2023-05-25 Casi Pharmaceuticals, Inc. Methods of blood screening
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2012076663A1 (en) * 2010-12-10 2012-06-14 Sanofi Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
WO2010040209A1 (en) 2008-10-06 2010-04-15 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
US20220281997A1 (en) 2019-09-27 2022-09-08 Nanjing GenScript Biotech Co., Ltd. Anti-VHH Domain Antibodies and Use Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2012076663A1 (en) * 2010-12-10 2012-06-14 Sanofi Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer;Tatiana A. Karakasheva等;《Cancer Res》;第4074-4085页 *
Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM);Laura Moreno等;《blood》;第2105页 *
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds;Rainer Boxhammer等;《blood》;第3015页 *
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies;Jutta Deckert等;《Clin Cancer Res》;第4574-4583页 *
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia;Alba Matas-Céspedes等;《Clin Cancer Res》;第1493-1505页 *
人CD38分子的克隆表达、单克隆抗体的制备及其功能的初步研究;温新宇;《中国博士学位论文全文数据库（电子期刊）医药卫生科技辑》;第51-54页"3.8 1C6对靶细胞的增殖抑制作用研究"、"3.9 1C6 CDC功能研究" *

Also Published As

Publication number Publication date
AU2018316522A1 (en) 2020-03-05
US20220135697A1 (en) 2022-05-05
AU2018316522B2 (en) 2025-02-20
US20200362050A1 (en) 2020-11-19
JP7299873B2 (ja) 2023-06-28
KR102770110B1 (ko) 2025-02-20
SG11202000484TA (en) 2020-02-27
WO2019034753A1 (en) 2019-02-21
CA3072296A1 (en) 2019-02-21
JP2020533965A (ja) 2020-11-26
US11236173B2 (en) 2022-02-01
EP3668543A1 (en) 2020-06-24
KR20200036861A (ko) 2020-04-07
US12162949B2 (en) 2024-12-10
CN111032086A (zh) 2020-04-17
NZ761838A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
JP7596447B2 (ja) Ｃｄ３８調節抗体
JP7467584B2 (ja) Ｃｄ３８調節抗体
CN111032086B (zh) Cd38抗体
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant